<DOC>
	<DOCNO>NCT01784614</DOCNO>
	<brief_summary>The aim study learn different dos LY2624803 affect sleep healthy Japanese participant . The study four treatment period . Participants receive single dose LY2624803 placebo treatment period .</brief_summary>
	<brief_title>A Study LY2624803 Japanese Participants With Transient Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Overtly healthy male female Japanese Women childbearing potential , test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study 3 month follow last dose study drug Body mass index ( BMI ) 17.6 26.4 kilogram per meter square ( kg/m^2 ) , inclusive Normal bedtime hour , routine time spend bed 6.5 hour 9 hour night Clinical laboratory test result within normal reference range Venous access sufficient allow blood sample per protocol Are reliable willing make available duration study willing able follow study procedure Have give write informed consent approve Lilly ethical review board govern site Within 4 month initial dose study drug , receive treatment drug receive regulatory approval indication Persons previously complete withdrawn study study investigate LY2624803 receive study drug Known allergy LY2624803 relate compound Women lactate Shift worker [ shift plan shift work within 7 day phase advance polysomnography ( PSG ) night ] person cross ( cross ) one time zone aircraft within 3 day prior entry Have irregular alter sleep/wake schedule likely prevent keep regular sleep/wake schedule study Regular napping ( â‰¥ 2 daytime naps/week history ) Extreme morning type even type Rhinitis , conjunctivitis , urticaria chronic pain severe enough interfere sleep Nocturia would interfere sleep assessment Symptoms consistent sleep disorder history Evidence significant active neuropsychiatric disease particular evidence significant medical psychiatric illness within past 12 month could contribute insomnia History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurocardiogenic neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data History presence orthostatic sign symptom within 2 year History seizure close relative seizure disorder ( epilepsy ) . History single febrile convulsion 10 year ago acceptable . History cranial trauma loss consciousness discuss prior include participant Abnormal movement observe outside normal sleep time Abnormal supine blood pressure and/or pulse rate Participants orthostatic hypotension screen An abnormality 12lead electrocardiogram ( ECG ) increase risk associate participate study Regular use know drug abuse and/or positive finding urinary drug screen Evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody Evidence hepatitis C and/or positive hepatitis C antibody Evidence hepatitis B and/or positive hepatitis B surface antigen Evidence syphilis infection and/or positive syphilis test Use intend use prescription ( except oral contraceptive ) , overthecounter herbal medication , specifically antihistamine , anticholinergic medication medication affect sleepiness , within 28 day prior Period 1 dose and/or study Participants donate 200 milliliter ( mL ) blood component blood within one month screening , donate 400 mL blood within 3 month screen History smoking within previous 6 month screen Participants average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , participant unwilling stop alcohol consumption period Participants whose daily caffeine intake permit maintenance usual sleep/wake schedule No response phase advance placebo responder Sleep disorder detect PSG screen night History presence breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>